Mediana and JLK to Build AI Platform for Stroke Prognosis Management

Establishing a Medical AI Innovation Ecosystem with "Dr. Answer 3.0"
Rising Demand for Post-Discharge Management and Benefits from Expansion of the DRG Payment System

Mediana announced on June 4 that it will collaborate with the medical artificial intelligence (AI) company JLK to build a digital prognosis management platform for stroke patients.

This project is part of "Dr. Answer 3.0," an initiative to establish a medical AI innovation ecosystem led by the Ministry of Science and ICT and the National IT Industry Promotion Agency (NIPA). Korea University Guro Hospital will also participate, conducting demonstrations in real clinical settings.

The two companies plan to link Mediana's wearable electrocardiogram (ECG) technology with JLK's AI-based stroke analysis technology to create a digital care model that can continuously manage patients' conditions after discharge. A key aspect of this project is expanding the use of medical AI from in-hospital diagnostic scenarios to post-discharge care.

Mediana explained that since stroke patients continue to face a risk of recurrence even after discharge, there will be growing demand for long-term post-discharge management through continuous monitoring of biometric signals. The company also expects that, with the expansion of the diagnosis-related group (DRG) payment system, demand from medical institutions for digital prognosis management solutions will increase.

In this project, Mediana will use its wearable ECG devices to collect key biometric signals such as heart rate, respiratory rate, and ECG data, providing a data infrastructure to enable long-term patient monitoring. The company is also working to establish a medical AI ecosystem that connects patient monitors (PM), central monitoring systems (CMS), and wearable medical devices on a single platform.

More recently, Mediana has been jointly developing a medical sovereign AI platform with companies such as FuriosaAI and SelvasAI, and is expanding its open medical AI platform business by integrating biometric data collected from patient monitors and wearable devices with a variety of medical AI solutions.

Seunghyun Yoon, CEO of Mediana, stated, "This project is significant as it combines patient monitoring technology and medical AI to extend into post-treatment care. Going forward, we plan to expand partnerships with various medical AI companies and further develop our platform business to help medical institutions improve treatment outcomes and reduce costs."

This content was produced with the assistance of AI translation services.